Anti sense oligonucleotides for blocking IgE receptor synthesis

• US 5,892,023 A
• Filed: 11/20/1997
• Issued: 04/06/1999
• Est. Priority Date: 05/26/1995
• Status: Expired due to Fees

• Current Assignee: Societe de Conseils de Recherches et d'Applications Scientifiques
• Original Assignee: Societe de Conseils de Recherches et d'Applications Scientifiques
• Inventors: Pirotzky, Eduardo, Colote, Soudhir
• Primary Examiner(s): Elliott, George C.
• Assistant Examiner(s): McGarry, Sean
• Application Number:
  US08/952,597
• Time in Patent Office: 502 Days
• Field of Search: 435/6, 435/172.3, 435/375, 435/377, 536/24.1, 536/24.5, 514/44
• US Class Current: 536/24.5
• CPC Class Codes: C12N 15/1138 against receptors or cell surface proteins
• CPC Class Codes: C12N 2310/315 Phosphorothioates
• CPC Class Codes: C12N 2310/337 in alpha-anomeric form
• CPC Class Codes: C12N 2310/351 Conjugate
• CPC Class Codes: C12N 2310/3515 Lipophilic moiety, e.g. cholesterol

Abstract

The invention is drawn to antisense oligonucleotides directed to the inhibition of the IgE receptor synthesis.

Claims

1. An oligonucleotide comprising 10 to 25 nucleotide units and which selectively hybridizes with at least one gene necessary to block the synthesis of the IgE receptor and comprises a sequence selected from the group consisting of SEQ ID Nos:

1 to 6.

2. An oligonucleotide as claimed in claim 1, that selectively hybridizes with genes or transcriptional products for the α

subunits of the high affinity IgE receptor.

3. An oligonucleotide as claimed in claim 1, which consists of a sequence selected from group consisting of SEQ ID No:

1 to SEQ ID No;

6.

4. An oligonucleotide as claimed in claim 1, in which the phosphate backbone is modified.

5. An oligonucleotide as claimed in claim 4, in which the nucleotidic base is modified.

6. An oligonucleotide as claimed in claim 5, in which a modified nucleotidic base presents the α

anomer conformation.

7. An oligonucleotide as claimed in claim 4, in which at least one of the phosphate bond groups is modified.

8. An oligonucleotide as claimed in claim 7, in which at least one of the phosphate bond groups is modified into phosphorothioate.

9. An oligonucleotide as claimed in claim 8, which consists of a sequence selected from the group consisting of SEQ ID No:

1 to SEQ ID No;

6.

10. An oligonucleotide as claimed in claim 4, in which either the 5'"'"' position or the 3'"'"' position or the 5'"'"' and 3'"'"' positions is modified.

11. An oligonucleotide as claimed in claim 10, in which either the 5'"'"' position or the 3'"'"' position or the 5'"'"' and 3'"'"' positions is modified by the substitution of a hydrophobic group.

12. An oligonucleotide as claimed in claim 10, in which either the 5'"'"' position or the 3'"'"' position or the 5'"'"' and 3'"'"' positions is modified by the substitution of a protector group.